517 related articles for article (PubMed ID: 14559824)
1. PTEN reverses MDM2-mediated chemotherapy resistance by interacting with p53 in acute lymphoblastic leukemia cells.
Zhou M; Gu L; Findley HW; Jiang R; Woods WG
Cancer Res; 2003 Oct; 63(19):6357-62. PubMed ID: 14559824
[TBL] [Abstract][Full Text] [Related]
2. The PTEN, Mdm2, p53 tumor suppressor-oncoprotein network.
Mayo LD; Donner DB
Trends Biochem Sci; 2002 Sep; 27(9):462-7. PubMed ID: 12217521
[TBL] [Abstract][Full Text] [Related]
3. Loss of tumor suppressor p53 decreases PTEN expression and enhances signaling pathways leading to activation of activator protein 1 and nuclear factor kappaB induced by UV radiation.
Wang J; Ouyang W; Li J; Wei L; Ma Q; Zhang Z; Tong Q; He J; Huang C
Cancer Res; 2005 Aug; 65(15):6601-11. PubMed ID: 16061640
[TBL] [Abstract][Full Text] [Related]
4. PTEN protects p53 from Mdm2 and sensitizes cancer cells to chemotherapy.
Mayo LD; Dixon JE; Durden DL; Tonks NK; Donner DB
J Biol Chem; 2002 Feb; 277(7):5484-9. PubMed ID: 11729185
[TBL] [Abstract][Full Text] [Related]
5. [Regulation of NF-kappaB/P65 by MDM2 in acute lymphoblastic leukemia in childhood].
Hu Q; Zhou MX; Liu SY; Zhang LQ; Liu AQ; Guo YJ; Song Y
Zhonghua Er Ke Za Zhi; 2003 Dec; 41(12):921-4. PubMed ID: 14723816
[TBL] [Abstract][Full Text] [Related]
6. p53 regulates cell survival by inhibiting PIK3CA in squamous cell carcinomas.
Singh B; Reddy PG; Goberdhan A; Walsh C; Dao S; Ngai I; Chou TC; O-Charoenrat P; Levine AJ; Rao PH; Stoffel A
Genes Dev; 2002 Apr; 16(8):984-93. PubMed ID: 11959846
[TBL] [Abstract][Full Text] [Related]
7. Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells.
Grünwald V; DeGraffenried L; Russel D; Friedrichs WE; Ray RB; Hidalgo M
Cancer Res; 2002 Nov; 62(21):6141-5. PubMed ID: 12414639
[TBL] [Abstract][Full Text] [Related]
8. Hepatitis B Virus X protein modulates the expression of PTEN by inhibiting the function of p53, a transcriptional activator in liver cells.
Chung TW; Lee YC; Ko JH; Kim CH
Cancer Res; 2003 Jul; 63(13):3453-8. PubMed ID: 12839924
[TBL] [Abstract][Full Text] [Related]
9. Phosphorylation of human p53 at serine 46 determines promoter selection and whether apoptosis is attenuated or amplified.
Mayo LD; Seo YR; Jackson MW; Smith ML; Rivera Guzman J; Korgaonkar CK; Donner DB
J Biol Chem; 2005 Jul; 280(28):25953-9. PubMed ID: 15843377
[TBL] [Abstract][Full Text] [Related]
10. Analysis of the PI-3-Kinase-PTEN-AKT pathway in human lymphoma and leukemia using a cell line microarray.
Abbott RT; Tripp S; Perkins SL; Elenitoba-Johnson KS; Lim MS
Mod Pathol; 2003 Jun; 16(6):607-12. PubMed ID: 12808067
[TBL] [Abstract][Full Text] [Related]
11. In vivo gene therapy of human bladder cancer with PTEN suppresses tumor growth, downregulates phosphorylated Akt, and increases sensitivity to doxorubicin.
Tanaka M; Grossman HB
Gene Ther; 2003 Sep; 10(19):1636-42. PubMed ID: 12923562
[TBL] [Abstract][Full Text] [Related]
12. Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779.
Shi Y; Gera J; Hu L; Hsu JH; Bookstein R; Li W; Lichtenstein A
Cancer Res; 2002 Sep; 62(17):5027-34. PubMed ID: 12208757
[TBL] [Abstract][Full Text] [Related]
13. Activation of PI3K/Akt pathway by PTEN reduction and PIK3CA mRNA amplification contributes to cisplatin resistance in an ovarian cancer cell line.
Lee S; Choi EJ; Jin C; Kim DH
Gynecol Oncol; 2005 Apr; 97(1):26-34. PubMed ID: 15790433
[TBL] [Abstract][Full Text] [Related]
14. Preferential killing of PTEN-null myelomas by PI3K inhibitors through Akt pathway.
Zhang J; Choi Y; Mavromatis B; Lichtenstein A; Li W
Oncogene; 2003 Sep; 22(40):6289-95. PubMed ID: 13679867
[TBL] [Abstract][Full Text] [Related]
15. Akt regulates COX-2 mRNA and protein expression in mutated-PTEN human endometrial cancer cells.
St-Germain ME; Gagnon V; Mathieu I; Parent S; Asselin E
Int J Oncol; 2004 May; 24(5):1311-24. PubMed ID: 15067356
[TBL] [Abstract][Full Text] [Related]
16. MDM2 induces NF-kappaB/p65 expression transcriptionally through Sp1-binding sites: a novel, p53-independent role of MDM2 in doxorubicin resistance in acute lymphoblastic leukemia.
Gu L; Findley HW; Zhou M
Blood; 2002 May; 99(9):3367-75. PubMed ID: 11964305
[TBL] [Abstract][Full Text] [Related]
17. PTEN tumour suppressor is linked to the cell cycle control through the retinoblastoma protein.
Paramio JM; Navarro M; Segrelles C; Gómez-Casero E; Jorcano JL
Oncogene; 1999 Dec; 18(52):7462-8. PubMed ID: 10602505
[TBL] [Abstract][Full Text] [Related]
18. [Impact of PI3K /Akt /mdm2 signaling pathway on the sensitivity of gastric cancer cell line SGC7901 to doxorubicin].
Ai YW; Yu HG; Yu JP; Yang Y; Li H; Hu XW; Luo HS
Zhonghua Zhong Liu Za Zhi; 2008 Jul; 30(7):494-7. PubMed ID: 19062713
[TBL] [Abstract][Full Text] [Related]
19. Activation of Akt/protein kinase B overcomes a G(2)/m cell cycle checkpoint induced by DNA damage.
Kandel ES; Skeen J; Majewski N; Di Cristofano A; Pandolfi PP; Feliciano CS; Gartel A; Hay N
Mol Cell Biol; 2002 Nov; 22(22):7831-41. PubMed ID: 12391152
[TBL] [Abstract][Full Text] [Related]
20. A new selective AKT pharmacological inhibitor reduces resistance to chemotherapeutic drugs, TRAIL, all-trans-retinoic acid, and ionizing radiation of human leukemia cells.
Martelli AM; Tazzari PL; Tabellini G; Bortul R; Billi AM; Manzoli L; Ruggeri A; Conte R; Cocco L
Leukemia; 2003 Sep; 17(9):1794-805. PubMed ID: 12970779
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
